Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma

Introduction. Epidermal growth factor receptor (EGFR) mutations are known as oncogene driver mutations and with EGFR mutations exhibit good response to the EGFR tyrosine kinase inhibitor Gefitinib. Some studies have shown that activation of estrogen and estrogen receptor α or β (ERα/β) promote adeno...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomed Res Int
Hlavní autoři: Liu, Chien-Ming, Chiu, Kuo-Liang, Chen, Tzu-Sheng, Chang, Shang-Miao, Yang, Shu-Yun, Chen, Li-Hsiou, Ni, Yung-Lun, Sher, Yuh-Pyng, Yu, Sung-Liang, Ma, Wen-Lung
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi Publishing Corporation 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4321093/
https://ncbi.nlm.nih.gov/pubmed/25692143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/642041
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky